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Multiple	sclerosis	 6	 132	 0	 0	
Neuromyelitis	Optica	 3 18 0	 0
Dementia	 0 12 0	 3
Parkinson’s	Disease	 2 27 0	 1
Multiple	System	Atrophy	 0 5 0	 0
Motor	Neurone	Disease		 0 2 0	 0
Autism	 0 1 0	 0
Traumatic	brain	injury	 1 3 0	 0
Chiasmal	compression	 2 6 0	 0
Optic	pathway	glioma	 0 2 0	 0
Schizophrenia 0 2 0	 0
Neurosarcoid 0 1 0	 0
Stroke	 0 3 0	 0
Migraine	 0 6 0	 1
Cluster	headache	 0 1 0	 0





















































































































































































































































































































































































































































































































































AD								 Controls	 AD											 Controls	 AD	 Controls	
Ascaso	et	al.216	 TD	 Both	 18	(36)	 41	(82)	 72.1	±	8.7	 72.9	±	7.9	 64.96	±	16.71***	 103.1	±	8.04	
Berisha	et	al.221	 TD	 One	 9	(9)	 8	(8)	 74.3	±	3.3	 74.3	±	5.8	 85.5	±	7.4	 93.8	±	10.4	
Chi	et	al.223	 TD	 One	 12	(12)	 17	(17)	 75.39	±	7.30	 75.29	±	5.84	 93.18	±	11.36	 99.44	±	8.88	
Garcia‐Martin	et	al.222	 SD	 One	 20	(20)	 28	(28)	 79.3	±	4.1	 72.1	±	5.1	 88.6	±	20.5	 89.2	±	20.9	
Gharbiya	et	al.224	 SD	 Both	 21	(42)	 21	(42)	 73.1	±	6.9	 70.3	±	7.3	 96.8	±	6.9	 95.9	±	8.5	
Günes	et	al.212	 SD	 One	 40	(40)	 40	(40)	 75.02	±	6.34	 74.15	±	5.76	 84.0	±	7.0	***	 107.1	±	6.3	
Iseri	et	al.219	 TD	 Both	 14	(28)	 15	(30)	 70.16	±	9.7	 65.1	±	9.8	 87.46	±	23.78***	 113.16	±	6.72	
Kang	et	al.215	 SD	 Both	 8	(16)	 8	(16)	 71.5	 67.4	 80.44	±	16.73*	 92.50	±	9.8	
Kesler	et	al.217	 TD	 Mix	 30	(52)	 24	(38)	 73.7	±	9.9	 70.9	±	9.2	 84.7	±	10.6*	 94.3	±	11.3	
Kirbas	et	al.214	 SD	 Both	 40	(80)	 40	(80)	 69.3	±	4.9	 68.9	±	5.1	 65.0	±	6.2***	 75.0	±	3.8	
Kromer	et	al.225	 SD	 Mix	 22	(42)	 22	(42)	 75.9	±	6.1	 64.0	±	8.2	 105	±	17.0	 101.8	±	10.7	
Larrosa	et	al.226	 SD	 One	 151	(151)	 61	(61)	 75.29	 74.87	 97.55	±	14.12	 100.55	±	12.99	
Moreno‐Ramos	et	al.227	 SD	 Both	 10	(20)	 10	(20)	 73.0	±	6.5	 70.2	±	5.5	 94.5	±	2.2***	 108.0	±	2.2	
Paquet	et	al.218	 TD	 Both	 26	(52)	 15	(30)	 78.5	±	4.91	 75.5	±	5.1	 83.4	±	7.19**	 102.2	±	1.8	
Parisi	et	al.210	 TD	 One	 17	(17)	 14	(14)	 70.37	±	6.1	 Age‐matched	 59.5	±	16.7**	 99.9	±	8.95	
Polo	et	al.213	 SD	 One	 75	(75)	 75	(75)	 74.15	±	9.15	 73.98	±	9.05	 97.40	±	11.2	 99.21	±	9.9	








































Heterogeneity: Tau² = 67.27; Chi² = 377.84, df = 16 (P < 0.00001); I² = 96%





















































































































































AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls



















Superior	 Inferior	 Temporal	 Nasal	
AD	 Controls	 AD	 Controls	 AD	 Controls	 AD	 Controls	
Ascaso	et	al.216	 76.58±21.90***	 127.4±14.0	 85.47±25.70***	 134.2±15.57	 56.47±15.86***	 75.34±15.05	 44.59±21.67***	 76.84±15.0	
Berisha	et	al.221	 92.2±21.6*	 113.6±10.8	 117.0±15.3	 128.1±11.4	 67.0±15.0	 69.5±11.1	 65.7±15.1	 64.1±7.3	
Chi	et	al.223	 115.09±14.05*		 127.94±12.29	 120.64±17.99	 129.56±15.17	 72.36±17.85	 74.69±11.72	 65.81±13.02	 65.31±8.99	
Garcia‐Martin	et	al.222	 101.4±16.5	 102.2±10.8	 110.8±11.1	 111.8±10.8	 71.8±12.5	 70.6±11.6	 70.5±12.8	 72.3±10.6	
Gharbiya	et	al.224	 114.9±13.8	 116.3±14.5	 126.9±12.7	 124.0±13.6	 72.6±14.9	 69.8±13.9	 74.9±11.5	 73.7±12.2	
Günes	et	al.212	 104±14.2	***	 126.5±14.0	 101.3±16.2	***	 135.9±16.3	 66.6±15.0	***	 80.2±16.7	 67.7	±	17.0	***	 85.4	±	13.5	
Iseri	et	al.219	 112.64±35.32**	 137.16±16.48	 103.10±33.64***	 141.56±19.09	 64.92±17.70	 72.30±16.42	 63.57±19.09***	 96.00±34.39	
Kang	et	al.215	 103.8±26.71	 113.5±20.75	 104.8±24.97*	 126.1±19.34	 58.38±13.24	 61.50±10.71	 55.31±12.61**	 68.81±11.35	
Kesler	et	al.217	 99.0±18.0*	 110.0±16.7	 110.1±19.1*	 127.0±15.5	 61.7±10.9	 67.8±15.1	 66.8±14.5	 76.4±21.8	
Kirbas	et	al.214	 76±6.7***	 105±4.8	 106±11.5	 108±8.7	 74±6.7	 77±7.3	 75±2.8	 76±2.7	
Larrosa	et	al.226	 113.22±18.67**	 117.81±19.00	 120.44±20.98***	 127.38±20.99	 64.47±21.76*	 67.83±20.01	 72.67±17.31	 74.55±17.26	
Parisi	et	al.210	 72.1±21.4**	 104.6±12.1	 77.9±26.4**	 116.2±9.87	 37.9±17.60**	 85.6±8.21	 50.4±23.2**	 93.4±13.7	
Polo	et	al.213	 113.59±14.5**	 118.58±10.8	 121.96±16.9*	 127.97±15.9	 65.00±10.2	 66.96±9.2	 71.61±15.0	 72.12±14.5	








































Heterogeneity: Tau² = 217.29; Chi² = 301.69, df = 13 (P < 0.00001); I² = 96%





























































































































AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls









































Heterogeneity: Tau² = 200.18; Chi² = 209.18, df = 13 (P < 0.00001); I² = 94%





























































































































AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls









































Heterogeneity: Tau² = 73.56; Chi² = 129.69, df = 13 (P < 0.00001); I² = 90%





























































































































AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls









































Heterogeneity: Tau² = 74.03; Chi² = 153.35, df = 13 (P < 0.00001); I² = 92%





























































































































AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls





















































MCI								 Controls	 MCI											 Controls	 MCI	 Controls	
Ascaso	et	al.216	 TD	 Both	 18	(36)	 41	(82)	 72.1	±	8.7	 72.9	±	7.9	 86.7	±	7.18***	 103.1	±	8.04	
Kesler	et	al.217	 TD	 Mix	 24	(40)	 24	(38)	 71.0	±	10.0	 70.9	±	9.2	 85.8	±	10.0*	 94.3	±	11.3	
Paquet	et	al.218	 TD	 Both	 23	(46)	 15	(30)	 78.7	±	6.2	 75.5	±	5.1	 89.3	±	2.7***	 102.2	±	1.8	
Shen	et	al.229	 SD	 Mix	 23	(45) 52	(104) 74.4	±	3.2	 74.1	±	2.6 82.6	±	10.5 85.6	±	10.2








Superior	 Inferior	 Temporal	 Nasal	
MCI	 Controls	 MCI	 Controls	 MCI	 Controls	 MCI	 Controls	
Ascaso	et	al.216	 100.3±15.5***	 127.4±14.0	 110.6±18.1***	 134.2±15.57	 67.38±14.32***	 75.34±15.05	 68.43±17.16***	 76.84±15.0	
Kesler	et	al.217	 101.3±15.2	 110.0±16.7	 111.9±16.1*	 127.0±15.5	 64.2±13.9	 67.8±15.1	 65.9±15.1	 76.4±21.8	
Shen	et	al.229	 101.8±16.8	 104.7±15.4	 104.5±17.6	 109.3±21.3	 62.7±12.2	 65.5±10.1	 61.5±8.1	 64.8±8.4	



































Heterogeneity: Tau² = 40.61; Chi² = 91.67, df = 4 (P < 0.00001); I² = 96%





















































MCI Controls Mean Difference Mean Difference
IV, Random, 95% CI








Heterogeneity: Tau² = 113.04; Chi² = 37.24, df = 3 (P < 0.00001); I² = 92%













































MCI Controls Mean Difference Mean Difference
IV, Random, 95% CI








Heterogeneity: Tau² = 83.85; Chi² = 25.75, df = 3 (P < 0.0001); I² = 88%













































Experimental Controls Mean Difference Mean Difference
IV, Random, 95% CI
































Heterogeneity: Tau² = 12.18; Chi² = 8.62, df = 3 (P = 0.03); I² = 65%













































MCI Controls Mean Difference Mean Difference
IV, Random, 95% CI








Heterogeneity: Tau² = 10.93; Chi² = 8.56, df = 3 (P = 0.04); I² = 65%













































MCI Controls Mean Difference Mean Difference
IV, Random, 95% CI







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0.961	 0.936	 0.961	 0.955	 0.958	


































































































































































































































































































































































Age	Range	 G	 PMB	 T	 TS	 NS	 N	 N/T	 NI	 TI	
10‐19	 99	 59	 78	 138	 102	 72	 0.92	 108	 147	
20‐29	 99	 59	 78	 138	 102	 72	 0.92	 108	 147	
30‐39	 98	 58	 76	 136	 102	 72	 0.94	 107	 145	
40‐49	 97	 57	 75	 135	 102	 72	 0.95	 106	 143	
50‐59	 96	 56	 73	 133	 102	 72	 0.96	 105	 141	
60‐69	 96	 55	 72	 132	 102	 72	 0.98	 104	 138	
70‐79	 95	 54	 70	 130	 102	 72	 0.99	 103	 136	






























































































































































































Drug	name	 generic	name	 method	of	admin	 effectiveness	
Avonex	 interferon	beta	1a	 injection;	weekly	 moderately	effective	
Betaferon	 interferon	beta	1b	 injection;	every	other	day	 moderately	effective	
Extavia	 interferon	beta	1b	 injection;	every	other	day	 moderately	effective	
Plegridy	 interferon	beta	1a	 injection;	2	weekly	 moderately	effective	
Rebif	 interferon	beta	1a	 injection;	3	times	a	week	 moderately	effective	
Copaxone	 glatiramer	acetate	 injection;	daily	 moderately	effective	
Aubagio	 teriflunomide	 oral;	daily	 moderately	effective	
Tecfidera	 dimethyl	fumarate	 oral;	twice	daily	 more	effective	
Gilenya	 fingolimod	 oral;	daily	 more	effective	







































































































































































Controls	 All	MS	 RRMS	 PPMS	 SPMS	
Number	 106	 655	 502	 21	 132	








‐0.4	±	1.5	 ‐0.4	±	1.4	 ‐0.4	±	1.2	 ‐0.37	±	1.52	 ‐0.29	±	2.06	
Disease	duration	
(months)	
‐	 139	±	109	 114	±	91	 135	±	109	 235	±	118	
Age	of	onset	(years)	 ‐	 32.1	±	9.1	 31.3	±	8.6	 37.0	±	11.5	 34.2	±	9.9	
On	treatment	(%)	 ‐	 32.7	(n=214)	 41.8	(n=210)	 4.7	(n=1)	 2.2	(n=3)	
Previous	optic	
neuritis	*	(%)	
‐	 24.4	(n=160)	 22.7	(n=114)	 23.8	(n=5)	 31.1	(n=41)	













































controls	 RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
pRNFL	
thickness:	
global	 101.0	±	10.9	 90.2	±	13.2***	 76.3	±	15.5***	 89.9	±	13.8**	 81.1	±	14.8***	
PMB	 57.5	±	7.7	 46.2	±	10.9***	 37.8	±	10.1***	 48.9	±	12.1**	 40.3	±	12.1***	
T	 74.9	±	10.8	 61.0	±	14.7***	 48.5	±	13.8***	 63.8	±	14.5**	 52.4	±	15.8***	
TS	 140.2	±	17.7	 127.9	±	18.8***	 110.2	±	21.7***	 127.1	±	25.8	**	 115.6	±	20.5	***	
NS	 101.2	±	20.7	 93.7	±	19.3***	 86.0	±	25.5***	 89.8	±	15.8**	 89.6	±	20.1***	
N	 76.5	±	13.1	 70.6	±	14.8***	 58.1	±	14.2***	 70.8	±	15.4	 63.5	±	15.6***	
N/T	 1.045	±	0.23	 1.219	±	0.363	***	 1.254	±	0.345***	 1.166	±	0.359	 1.294	±	0.397	***	
NI	 115.1	±	26.5	 105.3	±	25.6***	 90.8	±	26.6***	 101.6	±	22.5*	 95.3	±	23.3***	
TI	 148.7	±	18.4	 132.0	±	23.3***	 110.8	±	25.5***	 132.2	±	25.2**	 116.0	±	25.3	***	





























central	 275.2	±	18.4	 270.7	±	19.3*	 265.3	±	19.3***	 277.7	±	18.7	 265.6	±	20.3***	
IN	 348.8	±	12.4	 333.8	±	20.6***	 324.5	±	20.1***	 336.1	±	22.1*	 321.5	±	20.1***	
IS	 347.2	±	12.2	 333.7	±	19.5***	 324.4	±	17.4***	 334.8	±	20.1*	 321.3	±	19.2***	
IT	 333.7	±	12.7	 322.7	±	18.0***	 314.9	±	17.2***	 325.4	±	17.3*	 311.8	±	18.1***	
II	 344.9	±	12.6	 330.4	±	19.6***	 320.0	±	19.1***	 332.2	±	19.2**	 318.1	±	19.1***	
ON	 320.6	±	14.1	 303.9	±	19.6***	 293.0	±	17.1***	 302.3	±	22.6**	 289.8	±	19.8***	
OS	 301.4	±	12.2	 292.7	±	16.8***	 286.4	±	14.1***	 287.7	±	17.4**	 282.5	±	15.4***	
OT	 286.1	±	13.6	 279.7	±	13.6***	 275.1	±	12.8***	 277.8	±	14.7*	 270.8	±	14.4***	














































controls	 RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
Macular	full	
thickness	
volume	MV	 8.74	±	0.33	 8.43	±	0.43***	 8.21	±	0.41***	 8.41	±	0.46**	 8.12	±	0.42***	



















controls	 RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
sfCT	 322.3	±	92.5	 299.3	±	106.4*	 294.7	±	99.7*	 281.1	±	111.4	 275.0	±	84.4***	


































RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
global	RNFL	 ‐0.452	(<0.001)***	 ‐0.744	(<0.001)***	 0.068	(0.770)	 ‐0.273	(0.002)**	
temporal	RNFL	 ‐0.368	(<0.001)***	 ‐0.603	(<0.001)***	 ‐0.227	(0.322)	 ‐0.214	(0.014)*	
MV	 ‐0.178	(<0.001)***	 ‐0.436	(<0.001)***	 0.397(0.074)	 ‐0.128	(0.143)	
macular	GCLV	 ‐0.264	(<0.001)***	 ‐0.511	(<0.001)***	 ‐0.676	(0.001)**	 ‐0.205	(0.019)*	




























RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
CRAE	 28.08	±	2.17	 28.47	±	2.29	 28.29	±	2.30	 28.56	±	2.93	 28.20	±	2.36	
CRVE	 35.37	±	2.41	 36.57	±	2.89**	 37.30	±	3.15***	 35.42	±	2.80	 34.93	±	2.97	




































controls	 RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
aTort	 ‐9.04	±	0.92	 ‐8.97	±	0.94	 ‐9.26	±	1.05	 ‐9.01	±	1.30	 ‐9.17	±	0.84	
vTort	 ‐9.54	±	0.66	 ‐9.49	±	0.66	 ‐9.43	±	0.63	 ‐9.32	±	0.59	 ‐9.48	±	0.78	
























controls	 RRMS	‐	no	ON	 RRMS	+	ON	 PPMS	 SPMS	
aD0	 1.63	±	0.03	 1.62	±	0.12	 1.61	±	0.03*	 1.61	±	0.03*	 1.61	±	0.04*	
aD1	 1.62	±	0.03	 1.61	±	0.12	 1.60	±	0.03**	 1.60	±	0.03*	 1.60	±	0.04*	
aD2	 1.61	±	0.03	 1.59	±	0.12	 1.59	±	0.03*	 1.59	±	0.03*	 1.59	±	0.04*	
aDBOX	 1.13	±	0.02	 1.12	±	0.03	 1.11	±	0.02**	 1.11	±	0.02*	 1.11	±	0.03*	
vD0	 1.62	±	0.03	 1.60	±	0.12	 1.60	±	0.03*	 1.62	±	0.02	 1.60	±	0.04**	
vD1	 1.60	±	0.03	 1.58	±	0.12	 1.60	±	0.03	 1.60	±	0.02	 1.59	±	0.04	
vD2	 1.60	±	0.03	 1.58	±	0.12	 1.59	±	0.03	 1.59	±	0.02	 1.58	±	0.04	
vDBOX	 1.12	±	0.02	 1.11	±	0.03**	 1.11	±	0.02**	 1.12	±	0.01	 1.11	±	0.03*	
cD0	 1.80	±	0.02	 1.78	±	0.13	 1.79	±	0.02*	 1.79	±	0.02	 1.78	±	0.03*	
cD1	 1.79	±	0.02	 1.77	±	0.13	 1.78	±	0.03	 1.78	±	0.02	 1.77	±	0.03*	
cD2	 1.78	±	0.02	 1.76	±	0.13	 1.76	±	0.02*	 1.77	±	0.02	 1.76	±	0.03*	












































































































































































































































































































































































































































































































global	 101.0	±	10.9	 76.3	±	15.5***	 63.4	±	9.5***	
T	 74.9	±	10.8	 48.5	±	13.8***	 42.9	±7.5***	





Macular	GCLV	 1.12	±	0.08	 0.88	±	0.13***	 0.92	±	0.21***	
sfCT	 322.3	±	92.5	 294.7	±	99.7*	 333.8	±	82.2	
CRAE	 28.08	±	2.17	 28.29	±	2.30	 29.06	±	2.37	
CRVE	 35.37	±	2.41	 37.30	±	3.15***	 34.95	±	2.63	
AVR	 0.80	±	0.06	 0.75	±	0.07***	 0.83	±	0.05*	
aTort	 ‐9.04	±	0.92	 ‐9.26	±	1.05	 ‐8.86	±	0.94	
vTort	 ‐9.54	±	0.66	 ‐9.43	±	0.63	 ‐9.08	±	0.90	
aD1	 1.62	±	0.03	 1.60	±	0.03**	 1.61	±	0.03	













































































































































































































































































































































































































































































































Controls	 AD	 bvFTD	 PPA	 CBD	 PCA	
Number	 40	 58	 30	 17	 11	 24	
Mean	age	(years)	 57.6	±	6.6	 59.6	±	4.6	 60.8	±	2.6	 60.7	±	3.5	 61.6	±	2.7	 60.7	±	4.2	
Sex	(male:female)	 22:18	 33:25	 21:9	 9:8	 7:4	 13:11	
Refractive	error	
(dioptres)	 ‐0.24	±	1.42	 0.42	±	1.28	 ‐0.01	±	0.89	 0.55	±	1.29	 0.00	±	1.75	 ‐0.21	±	1.40	
Disease	duration	
(months)	 ‐	 46	±	32	 39	±	31	 52	±	28	 43	±	18	 51	±	30	
Age	of	onset	
(years)	 ‐	 55.8	±	4.7	 57.6	±	3.6	 56.4	±	3.4	 58.0	±	3.1	 56.5	±	4.5	




















AD	 bvFTD	 PPA	 CBD	 PCA	
pRNFL	
thickness	
global	 97.6±8.5	 92.1±9.8**	 96.1±9.6	 97.1±6.3	 98.5±12.2	 94.4±8.2	
PMB	 57.1±7.5	 51.6±9.1**	 55.7±10.2	 53.1±7.9	 55.8±12.4	 55.4±13.4	
T	 73.8±9.8	 66.4±12.4**	 68.9±11.0	 68.2±7.4	 69.4±16.9	 71.5±14.4	
TS	 141.1±17.8	 128.5±15.0***	 134.8±20.0	 140.4±13.4	 133.1±20.2	 134.4±16.5	
NS	 105.4±19.5	 96.4±16.4**	 102.6±16.9	 99.7±13.9	 101.8±21.4	 104.9±24.4	













NI	 114.8±24.5	 110.2±23.2	 117.6±17.9	 105.8±11.4	 120.5±19.0	 99.7±19.4**	






































central	 276.9	±	16.5	 278.5	±	18.6	 275.7	±	25.4	 286.9	±	19.2	 271.9	±	14.5	
IN	 347.9	±	11.4	 341.5	±	15.7*	 341.2	±	19.5	 346.8	±	11.4	 339.9	±	6.7**	
IS	 346.3	±	12.5	 340.4	±	15.1*	 338.5	±	15.5*	 342.2	±	11.1	 340.4	±	8.2	
IT	 332.6	±	12.2	 328.4	±	16.9	 327.9	±	16.2	 331.1	±	9.7	 327.4	±	8.3	
II	 343.6	±	12.3	 336.1	±	15.8*	 335.9	±	18.7	 341.1	±	11.3	 336.4	±	8.2*	
ON	 319.2	±	12.4	 311.5	±	13.1**	 307.7	±	12.3***	 310.2	±	10.9*	 313.3	±	6.8*	
OS	 301.3	±	11.8	 295.3	±	11.3*	 292.4	±	10.1**	 293.3	±	11.5*	 295.4	±	5.4*	
OT	 284.8	±	12.9	 283.1	±	14.5	 281.6	±	10.7	 278.4	±	12.3	 281.5	±	9.7	
OI	 291.7	±	12.0	 286.3	±	12.5*	 280.8	±	7.9***	 284.4	±	13.7	 287.9	±	7.0	


















































controls	 AD	 bvFTD	 PPA	 CBD	
Macular	full	
thickness	
volume	MV	 8.72	±	0.31	 8.58	±	0.34*	 8.49	±	0.29**	 8.55	±	0.31	 8.57	±	0.16*	
Macular	GCLV	 1.11	±	0.06	 1.05	±	0.07***	 1.00	±	0.08***	 1.02	±	0.06***	 1.08	±	0.05*	

















controls	 AD	 bvFTD	 PPA	 CBD	 PCA	
sfCT	 310.8	±	88.2	 265.9±53.0**	 230.7±72.6***	 233.8±81.5**	 262.6±22.0**	 251.4±98.4*	















































AD	 bvFTD	 PPA	 CBD	 PCA	
gRNFL	 ‐0.373	(0.004)	 0.154	(0.417)	 0.056	(0.832)	 0.343	(0.301)	 0.126	(0.556)	
tRNFL	 ‐0.137	(0.305)	 0.109	(0.565)	 ‐0.255	(0.322)	 0.329	(0.324)	 0.070	(0.744)	
MV	 ‐0.122	(0.362)	 0.408	(0.025)	 0.754	(<0.001)***	 ‐0.374	(0.257)	 ‐	
mGCLV	 ‐0.127	(0.340)	 0.271	(0.148)	 0.369	(0.145)	 ‐0.491	(0.125)	 ‐	


































AD	 bvFTD	 PPA	 CBD	 PCA	
CRAE	 27.96	±	1.99	 28.42	±	2.89	 28.72	±	2.64	 29.50	±	2.68	 29.34	±	2.49	 28.78	±	2.46	
CRVE	 34.95	±	2.37	 36.11	±	2.71*	 35.96	±	2.75	 36.17	±	2.22	 37.03	±	2.13*	 36.01	±	3.28	
AVR	 0.80	±	0.05	 0.78	±	0.07	 0.80	±	0.07	 0.82	±	0.05	 0.79	±	0.06	 0.80	±	0.07	




























controls	 AD	 bvFTD	 PPA	 CBD	 PCA	
aTort	 ‐9.06	±	0.97	 ‐9.01	±	0.95	 ‐9.11	±	0.84	 ‐9.24	±	1.03	 ‐9.24	±	0.76	 ‐8.90	±	0.90	
vTort	 ‐9.65	±	0.64	 ‐9.42	±	0.63	 ‐9.57	±	0.68	 ‐9.20	±	0.83	 ‐9.23	±	1.01	 ‐9.45	±	0.81	




































AD	 bvFTD	 PPA	 CBD	 PCA	
aD0	 1.63	±	0.04	 1.61	±	0.04**	 1.60	±	0.04**	 1.63	±	0.04	 1.58	±	0.03***	 1.59	±	0.03***	
aD1	 1.62	±	0.04	 1.59	±	0.04**	 1.59	±	0.04**	 1.61	±	0.03	 1.57	±	0.03***	 1.58	±	0.03***	
aD2	 1.61	±	0.04	 1.59	±	0.04**	 1.58	±	0.04**	 1.60	±	0.03	 1.56	±	0.03***	 1.57	±	0.03***	
aDBOX	 1.13	±	0.03	 1.11	±	0.03**	 1.11	±	0.03**	 1.12	±	0.03	 1.09	±	0.02***	 1.10	±	0.03***	
vD0	 1.62	±	0.03	 1.60	±	0.04*	 1.60	±	0.04*	 1.61	±	0.04	 1.61	±	0.03	 1.58	±	0.04***	
vD1	 1.60	±	0.03	 1.59	±	0.04*	 1.59	±	0.04*	 1.59	±	0.03	 1.59	±	0.03	 1.57	±	0.04***	
vD2	 1.59	±	0.03	 1.58	±	0.04*	 1.58	±	0.04*	 1.59	±	0.03	 1.58	±	0.03	 1.56	±	0.04***	
vDBOX	 1.12	±	0.02	 1.11	±	0.03*	 1.10	±	0.03*	 1.11	±	0.02	 1.11	±	0.03	 1.09	±	0.03***	
cD0	 1.80	±	0.03	 1.78	±	0.03***	 1.78	±	0.04**	 1.80	±	0.03	 1.77	±	0.03**	 1.77	±	0.03***	
cD1	 1.79	±	0.03	 1.77	±	0.03***	 1.76	±	0.03**	 1.78	±	1.71	 1.76	±	0.03**	 1.75	±	0.03***	
cD2	 1.78	±	0.03	 1.76	±	0.03***	 1.75	±	0.03**	 1.77	±	0.02	 1.75	±	0.03*	 1.74	±	0.03***	






















































































































































































































































































































































































































































































Number	 20	 20	 ‐	
Mean	age	(years)	 55.6	±	13.5	 57.9	±	12.8	 0.59	
Sex	(male:female)	 16:4	 16:4	 ‐	
Refractive	error	*	(dioptres)	 ‐0.60	±	1.91	 0.45	±	2.43	 0.13	
Disease	duration	(months)	 ‐	 20.2	±	14.5	 ‐	
Age	of	onset	(years)	 ‐	 55.6	±	12.7	 ‐	
Spinal‐onset	‐	n	(%)	 ‐	 10	(50)	 ‐	
On	riluzole	‐	n	(%)	 ‐	 11	(55)	 ‐	




























global	 98.5	±	5.8	 98.4	±	15.5	 99.0	±	13.7	 97.8	±	14.7	
PMB	 58.3	±	10.2	 52.5	±	7.4	 54.5	±	8.5	 50.6	±	5.9*	
T	 76.4	±	13.6	 69.5	±	10.4	 70.2	±	12.1	 68.9	±	8.9	
TS	 134.4	±	23.2	 125.8	±	17.1	 127.2	±	16.3	 124.4	±	18.5	
NS	 99.7	±	24.0	 95.5	±	21.1	 101.2	±	24.1	 89.7	±	17.1	
N	 75.2	±	18.8	 72.2	±	13.1	 73.0	±	11.9	 71.3	±	14.8	
N/T	 1.019	±	0.293	 1.116	±	0.280	 1.112	±	0.302	 1.120	±	0.273	
NI	 112.4	±	31.8	 111.8	±	28.3	 112.7	±	27.8	 110.9	±	30.27	


























central	 269.0	±	17.2	 281.5	±	24.0	 286.3	±	23.6	 276.8	±	24.7	
IN	 343.8	±	12.5	 342.7	±	18.8	 339.5	±	20.6	 345.9	±	17.4	
IS	 342.6	±	12.9	 341.1	±	18.1	 336.8	±	19.3	 345.4	±	16.7	
IT	 329.4	±	12.5	 330.0	±	17.3	 327.1	±	19.3	 333.0	±	15.6	
II	 340.7	±	13.3	 338.5	±	16.3	 335.7	±	17.9	 341.3	±	14.9	
ON	 314.9	±	13.8	 307.1	±	13.3	 304.1	±	13.9	 310.1	±	12.6	
OS	 297.6	±	12.2	 293.5	±	12.9	 291.8	±	13.4	 295.2	±	12.8	
OT	 281.6	±	12.6	 279.5	±	13.5	 276.5	±	14.7	 282.5	±	12.3	
OI	 289.5	±	15.2	 282.4	±	12.2	 280.4	±	12.6	 284.4	±	12.2	



























volume	MV	 8.61	±	0.34	 8.50	±	0.37	 8.44	±	0.40	 8.57	±	0.35	



















sfCT	 292.8	±	71.7	 268.4	±	99.6	 246.0	±	100.0	 291.2	±	98.4	



























































































CRAE	 28.06	±	2.30	 28.44	±	1.90	 28.96	±	1.54	 27.92	±	2.16	
CRVE	 35.51	±	2.28	 35.66	±	2.91	 36.02	±	3.37	 35.29	±	2.50	
AVR	 0.79	±	0.07	 0.80	±	0.06	 0.81	±	0.08	 0.79	±	0.04	


















aTort	 ‐9.11	±	1.02	 ‐9.12	±	0.78	 ‐8.71	±	0.78	 ‐9.52	±	0.56	






















aD0	 1.63	±	0.03	 1.60	±	0.04*	 1.62	±	0.04	 1.58	±	0.04**	
aD1	 1.61	±	0.03	 1.59	±	0.04*	 1.60	±	0.04	 1.57	±	0.04**	
aD2	 1.61	±	0.03	 1.58	±	0.04*	 1.59	±	0.03	 1.56	±	0.04**	
aDBOX	 1.13	±	0.02	 1.11	±	0.03*	 1.12	±	0.02	 1.09	±	0.03**	
vD0	 1.62	±	0.03	 1.60	±	0.04*	 1.61	±	0.02	 1.59	±	0.05	
vD1	 1.61	±	0.03	 1.59	±	0.03*	 1.59	±	0.03	 1.58	±	0.05	
vD2	 1.60	±	0.03	 1.58	±	0.03*	 1.58	±	0.02	 1.57	±	0.05	
vDBOX	 1.12	±	0.02	 1.11	±	0.02*	 1.11	±	0.02	 1.10	±	0.03	
cD0	 1.80	±	0.02	 1.78	±	0.03**	 1.79	±	0.02	 1.77	±	0.04*	
cD1	 1.79	±	0.02	 1.76	±	0.03**	 1.77	±	0.02	 1.75	±	0.04*	
cD2	 1.78	±	0.02	 1.75	±	0.03**	 1.77	±	0.02	 1.74	±	0.04*	
cDBOX	 1.26	±	0.01	 1.24	±	0.02**	 1.25	±	0.02	 1.23	±	0.03*	



























































































































global	 98.5	±	5.8	 98.4	±	15.5	 81.1	±	14.8***	





Macular	GCLV	 1.06	±	0.07	 1.02	±	0.10	 0.86	±	0.15***	
sfCT	 292.8	±	71.7	 268.4	±	99.6	 275.0	±	84.4	
CRAE	 28.06	±	2.30	 28.44	±	1.90	 28.20	±	2.36	
CRVE	 35.51	±	2.28	 35.66	±	2.91	 34.93	±	2.97	
AVR	 0.79	±	0.07	 0.80	±	0.06	 0.81	±	0.09	
aTort	 ‐9.11	±	1.02	 ‐9.12	±	0.78	 ‐9.17	±	0.84	
vTort	 ‐9.57	±	0.65	 ‐9.47	±	0.70	 ‐9.48	±	0.78	
aD1	 1.61	±	0.03	 1.59	±	0.04*	 1.60	±	0.04*	
vD1	 1.61	±	0.03	 1.59	±	0.03*	 1.59	±	0.04*	
	 	 	 	
		Abbreviations:	T,	temporal;	MV,	macular	volume;	GCLV,	ganglion	cell	layer	volume;	sfCT,	sub‐foveal	
choroidal	thickness;	CRAE,	central	retinal	arteriolar	equivalent;	CRVE,	central	retinal	venular	equivalent;	
AVR,	arterio‐venous	ratio;	aTort,	arteriolar	tortuosity;	vTort,	venular	tortuosity;	aD1,	arteriolar	fractal	
dimension	1;	vD1,	venular	fractal	dimension	1	
		NOTE.	Right	eye	analysis	only.	Data	are	shown	mean	±	SD	(μm)		
		*P	<	0.05,	**P	<	0.01,	***P	<	0.001.	
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With	global	and	temporal	RNFL	thickness	measures	both	showing	very	good	
discrimination,	there	is	therefore	clinical	value	in	using	these	measures	to	discriminate	
between	ALS	and	SPMS.	They	both	independently	have	very	good	specificity	and	
sensitivity,	but	when	combined,	this	improves	further.	
For	global	RNFL	thickness	less	than	95.5µm,	and	temporal	RNFL	thickness	less	than	
57.5µm,	SPMS	can	be	discriminated	from	ALS	with	92.4%	specificity,	and	88.0%	
sensitivity.	
Macular	volume	and	macular	GCL	volume	did	also	distinguish	SPMS	from	ALS	with	
acceptable	discrimination,	although	not	as	well	as	RNFL.	
	
So,	in	the	clinical	situation	of	an	uncertain	diagnosis,	RNFL	measures	can	be	used	to	
distinguish	between	ALS	and	SPMS.	
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Discussion	
	
This	is	the	first	study	to	look	at	neuroretinal	markers	in	ALS,	in	a	Scottish	population.		
Having	identified	conflict	and	unanswered	questions	from	the	literature,	I	have	
investigated	the	utility	of	neuronal	and	vascular	markers	in	the	retina	in	association	
with	spinal‐onset	and	bulbar‐onset	ALS.		
I	have	studied	diagnostic	phenotyping,	and	uncovered	several	novel	findings.	
	
Summary	
I	recruited	20	clinically	definite	ALS	patients,	10	spinal‐onset	ALS	and	10	bulbar‐onset	
ALS.	The	male:female	ratio	was	16:4,	and	11	of	the	patients	were	on	riluzole	treatment.	
RNFL,	MV	and	GCLV	
I	found	that	whilst	there	was	trend	towards	RNFL	thinning	in	ALS,	this	was	not	
significant,	apart	from	a	thinner	PMB	sector	of	the	RNFL	in	bulbar‐onset	ALS.		
However,	cluster	analysis	revealed	that	in	fact	there	were	two	clusters	of	ALS	patients,	
with	one	cluster	(n=4)	having	significantly	thinner	global	RNFL.	No	clinical	phenotype	
aligned	to	this	sub‐group,	they	were	not	the	oldest	patients	nor	those	with	the	longest	
disease	duration.	The	mechanism	of	this	RNFL	thinning	then	is	unclear.	
ALS	was	not	associated	with	macular	thinning	of	any	macular	sector,	or	reduced	
macular	volume.		
Bulbar‐onset	ALS	showed	a	trend	for	reduction	in	macular	GCL	volume,	but	this	was	
not	significant.	
Global	RNFL	thickness	and	temporal	RNFL	thickness	both	discriminated	very	well	
between	ALS	and	SPMS	with	high	specificity	and	sensitivity.	
Macular	volume	and	macular	GCL	volume	both	discriminated	acceptably	between	ALS	
and	SPMS.	
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Choroid	
No	previous	studies	have	investigated	choroidal	thickness	in	ALS.	
I	found	that	the	subfoveal	choroid	was	thinner	in	spinal‐onset	ALS,	but	this	did	not	
reach	significance.	
However,	ALS	patients	on	riluzole	treatment	had	significantly	thinner	choroid,	
compared	with	healthy	controls.	The	reason	for	this	is	unknown.	
Retinal	vessel	calibre,	tortuosity	and	fractal	dimension	
Retinal	vessel	parameters	have	not	previously	been	studied	in	ALS.	
In	this	study,	I	have	found	that	ALS	is	not	associated	with	retinal	vessel	morphological	
change,	with	the	exception	of	reduced	arteriolar	(multi‐fractal)	fractal	dimension	in	
bulbar‐onset	ALS.	
Vessel	calibre	and	vessel	tortuosity	were	not	significantly	different	in	ALS,	when	
analysed	as	a	whole	group.	However,	arteriolar	tortuosity	was	significantly	lower	in	
bulbar‐onset	ALS,	compared	with	spinal‐onset	ALS,	with	acceptable	discrimination,	and	
90%	specificity.	
Arteriolar	fractal	dimension	was	also	significantly	reduced	in	bulbar‐onset	ALS,	
compared	with	spinal‐onset	ALS,	again	with	acceptable	discrimination,	and	80%	
specificity.	
There	were	no	significant	differences	in	these	vessel	parameters	between	patients	on	
riluzole	treatment,	and	patients	who	were	not	on	treatment.	
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Utility	as	a	biomarker	
	
 Detection	method	should	be	precise,	reliable	and	transferrable	
True	for	all	OCT	imaging	derived	measures:	RNFL,	MV,	GCL,	sfCT	
True	for	all	VAMPIRE	retinal	vessel	measures:	calibre,	tortuosity,	fractal	dimension	
	
 Distinguish	between	healthy	and	disease	
True	for	RNFL	in	a	small	cluster	of	ALS	patients;	sfCT	for	ALS	patients	on	riluzole	
treatment	
Not	true	for	RNFL	in	the	majority	of	patients;	MV	in	ALS;	GCLV	in	ALS;	sfCT	for	ALS	
patients	not	on	riluzole	treatment;	calibre	in	ALS;	tortuosity	in	ALS	
	
 Differentiate	between	diseases	that	are	clinical	similar	
True	for	tRNFL	(ALS	and	SPMS);	tRNFL	(ALS	and	SPMS);	MV	(ALS	and	SPMS),	
GCLV	(ALS	and	SPMA);	arteriolar	tortuosity	(spinal‐onset	and	bulbar‐onset	ALS);	
arteriolar	fractal	dimension	(spinal‐onset	and	bulbar‐onset	ALS)	
Other	markers	not	assessed	
	
 Value	as	a	prognostic	marker	
Not	assessed	in	this	research	study	
	
 Use	in	monitoring	disease	progression	
Not	assessed	in	this	research	study	
	
 Use	as	a	pre‐clinical	screening	test	
Not	assessed	in	this	research	study	
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Contributions	to	knowledge	
	
 Amyotrophic	lateral	sclerosis	is	associated	with	a	thinner	RNFL	in	a	small	
cluster	of	patients,	thinner	choroid	when	on	riluzole	treatment,	and	a	reduced	
arteriolar	and	venular	fractal	dimension;	but	has	normal	RNFL	(in	most	
patients),	macular	thickness,	macular	volume,	macular	GCL	volume,	retinal	
vessel	calibre	and	retinal	vessel	tortuosity.	
	
 Bulbar‐onset	amyotrophic	lateral	sclerosis	is	associated	with	a	thinner	PMB	
sector	of	RNFL,	and	reduced	arteriolar	fractal	dimension;	but	has	normal	
macular	thickness,	macular	volume,	macular	GCL	volume,	retinal	vessel	calibre	
and	retinal	vessel	tortuosity	
	
 Spinal‐onset	amyotrophic	lateral	sclerosis	is	not	associated	with	any	
neuroretinal	marker,	with	no	value	significantly	different	from	controls.	
	
 Regarding	discrimination	between	ALS	subtypes,	arteriolar	tortuosity	and	
arteriolar	fractal	dimension	both	discriminated	between	bulbar‐onset	and	
spinal‐onset	ALS.	
	
	
	
Conclusion	
Despite	some	significant	findings,	it	is	unlikely	that	retinal	markers	of	neuronal	and	
vascular	integrity	will	have	clinical	utility	in	diagnostic	phenotyping	of	ALS.	
There	was	discrimination	between	ALS	subtypes	using	retinal	vessel	morphological	
parameters,	but	the	clinical	value	in	this	is	low.	
The	cluster	analysis	of	RNFL	thickness	in	ALS	that	revealed	a	small	cluster	of	ALS	
patients	with	significant	RNFL	thinning	is	intriguing,	but	probably	more	relevant	to	the	
pathology	of	ALS	than	any	potential	as	a	future	biomarker	of	this	disease.	
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7	 CONCLUSIONS	
	
Research	findings	
	
In	this	research	study,	I	have	explored	the	clinical	utility	of	retinal	imaging	derived	
biomarkers	of	neuroretinal	and	neurovascular	metrics	in	the	diagnosis	and	monitoring	
of	MS,	early‐onset	dementia	and	ALS.	
	
Overview	
The	three	phases	of	my	research	have	been:		
1.	systematic	reviews	of	the	literature	for	different	retinal	biomarkers	of	
neurodegenerative	disease,	including	meta‐analyses	of	the	most	studied	markers	
2.	detailed	description	and	expansion	on	the	required	methodology	for	reliable	retinal	
imaging	and	image	analysis,	including	a	novel	modulation	of	image	analysis	software	to	
extend	the	utility	of	single‐episode	patient	retinal	imaging	
3.	In	depth	analysis	of	the	clinical	utility	of	both	neuronal	and	vascular	metrics	in	the	
phenotyping	of	multiple	sclerosis,	early‐onset	dementia	syndromes	and	amyotrophic	
lateral	sclerosis.	
Systematic	reviews	
In	these	reviews,	I	started	with	a	systematic	review	for	the	use	of	OCT	technology	in	
informing	on	neurological	disease.	This	showed	a	sizable	presence	of	work	on	MS,	and	
several	studies	in	dementia	and	Parkinson’s	disease,	but	only	a	scattering	of	other	
diseases.	Notable	absences	were	non‐AD	dementias,	and	early‐onset	dementia.		
Reviewing	the	literature	on	MS,	it	was	clear	that	the	evidence	for	RNFL	measures	as	a	
surrogate	of	brain	atrophy	was	substantial,	and	accepted.	What	remained	unclear	
however	was	the	detail	in	RNFL	and	other	neuroretinal	measures,	in	regard	to	their	
discriminatory	potential,	and	clinical	utility	in	comparison	with	functional	
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characteristics,	such	as	visual	acuity.	There	were	also	no	imaging	studies	on	retinal	or	
choroidal	vasculature	in	MS.	
In	dementia,	the	focus	has	purely	been	on	Alzheimer’s	disease,	and	mild	cognitive	
impairment.	A	meta‐analysis	of	these	studies	of	RNFL	change	in	AD	(and	MCI)	revealed	
a	significant	finding	of	moderate	RNFL	thinning	in	AD.	A	second	meta‐analysis	of	retinal	
vessel	metrics	in	AD	showed	an	extremely	heterogenous	group	of	studies,	with	variable	
methodology	and	varied	results.	
There	were	no	studies	on	either	neuroretinal	or	retinal	vascular	markers	in	early‐onset	
dementia,	or	in	any	non‐AD	dementia,	such	as	FTD,	PPA,	CBD	or	PCA.	And	no	studies	of	
correlation	with	other	AD	markers,	such	as	CSF	biomarkers.	
ALS	had	just	three	published	studies	relating	to	neuroretinal	associations,	with	
methodological	weaknesses	and	conflicting	results.	There	were	no	studies	of	retinal	
vascular	markers	or	the	choroid	in	ALS.	
Therefore,	there	were	clear	unanswered	questions	regarding	the	utility	of	OCT	imaging	
(including	retinal	vascular	morphology	assessment)	in	these	diseases.	
Methodology	
The	rapid	evolution	of	retinal	imaging	devices	has	now	delivered	us	devices	with	
extraordinary	capability.	However,	it	is	essential	for	reliable	data	that	the	devices	are	
operated	by	informed	and	trained	users,	supported	by	good	analysis	tools,	and	
underpinned	by	a	thorough	understanding	of	ocular	anatomy,	physiology,	pathology	
and	imaging.	
In	this	thesis,	I	have	detailed	some	of	the	most	important	steps	in	retinal	imaging	
acquisition,	review,	processing	and	analysis.	This	includes	a	novel	methodological	
innovation,	of	analysing	the	retinal	vessel	morphology	from	the	OCT	SLO	images,	using	
bespoke	modulated	semi‐automated	software.	Therefore,	this	is	the	first	ever	study	to	
analyse	and	calculate	vessel	metrics	such	as	fractal	dimension	from	SPECTRALIS	SLO	
images.		
Analysis	studies	
The	three	clinical	diseases	of	MS,	early‐onset	dementia	(including	non‐AD	dementia	
types),	and	ALS	were	highlighted	and	chosen	from	my	literature	review.	
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I	recruited	almost	a	thousand	participants	to	this	research	study,	performed	all	the	
retinal	imaging,	processing	and	analysis,	and	have	presented	here	my	detailed	findings,	
including	many	novel	findings.	
The	breadth	and	depth	of	this	research	adds	significant	knowledge	to	the	field.		
Contributions	to	knowledge	
MS	
 Relapsing‐remitting	multiple	sclerosis	with	a	history	of	optic	neuritis,	was	
associated	with	the	greatest	reduction	in	RNFL	thickness,	in	all	sectors,	and	in	
macular	GCL	volume.	It	was	also	associated	with	thicker	venules,	and	lower	
arterio‐venous	ratio.	AVR	discriminated	between	RRMS	and	SPMS	with	very	
good	discrimination.	In	addition,	treatment‐naïve	RRMS	patients	were	
associated	with	a	lower	AVR.	
	
 Secondary‐progressive	MS	was	associated	with	the	greatest	reductions	in	
macular	thickness,	macular	volume	and	sub‐foveal	choroidal	thickness.	
	
 The	choroidal	thinning	seen	in	all	MS	subtypes	did	not	correlate	with	duration	
of	disease	or	visual	acuity,	but	was	thinner	in	RRMS	patients	on	treatment,	
versus	treatment‐naïve.		
	
 Retinal	vessel	tortuosity	was	not	associated	with	any	MS	subtype,	but	was	
associated	with	optic	neuritis	history	in	RRMS	(reduced	arteriolar	tortuosity	
with	ON	history).		
	
 Reduced	retinal	vessel	fractal	dimension	was	found	in	all	MS	subtypes,	mainly	
of	the	arteriolar	tree,	and	to	the	greatest	degree	in	SPMS	and	RRMS	+ON.		
	
 GCL	volume	measures	were	superior	to	RNFL	measures	in	diagnosing	MS,	
although	GCL	and	tRNFL	both	discriminated	MS	with	high	specificity.	Macular	
volume	and	choroidal	thickness	were	much	less	useful	in	discriminating	MS.	
GCL	volume	measures	were	also	more	stable	than	RNFL	over	the	short‐term,	
reflecting	the	vulnerability	of	the	RNFL	to	fluid	changes	and	variation.	Finally,	
GCL	volume	falls	earlier	in	RRMS	disease	course	than	RNFL	
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 Visual	acuity	in	SPMS	was	strongly	correlated	with	RNFL	thickness	(particularly	
temporal	RNFL)	and	macular	GCLV,	at	all	contrast	levels.	GCLV	showed	the	best	
correlation,	but	tRNFL	proved	the	more	reliable	comparator.	
	
 Thicker	retinal	venules	and	higher	arteriolar	tortuosity	were	both	predictive	of	
greater	relapse	rate	in	RRMS.	This	was	elevated	further	in	patients	with	tRNFL	
less	than	56µm,	a	higher	CRVE	(above	35px)	was	associated	with	a	2x	higher	
risk	of	at	least	one	relapse	in	the	next	year.		
	
 Regarding	discrimination	between	RRMS	and	NMO,	temporal	RNFL,	global	
RNFL,	N/T	ratio,	GCLV,	AVR	and	CRVE	were	all	significantly	different	between	
RRMS	+ON	and	NMO.	AVR	was	the	highest	single	discriminant,	but	a	combined	
score	using	cutoffs	in	tRNFL,	gRNFL	and	N/T	ratio	discriminated	NMO	from	
RRMS	+ON	with	94.6%	specificity.	
	
Dementia	
 Early‐onset	Alzheimer’s	disease	is	associated	with	global	RNFL	thinning	
(especially	superiorly),	macular	thinning,	reduced	macular	volume,	reduced	
GCL	volume,	and	reduced	retinal	arteriolar	and	venular	fractal	dimensions;	but	
has	normal	retinal	arterioles,	and	retinal	vessel	tortuosity.	There	was	no	
correlation	between	RNFL	or	GCL	volume	and	CSF	biochemical	markers	of	
dementia	in	early‐onset	AD.	
	
 Behavioural‐variant	frontotemporal	dementia	is	associated	with	macular	
thinning,	reduced	macular	volume,	reduced	GCL	volume,	choroidal	thinning,	
and	reduced	retinal	arteriolar	and	venular	fractal	dimension;	but	has	normal	
RNFL,	retinal	arterioles,	and	retinal	vessel	tortuosity.	However,	the	RNFL	
thickness	measure	predicts	cognitive	decline	in	bvFTD.	
	
 Primary	progressive	aphasia	is	associated	with	partial	macular	thinning,	
reduced	GCL	volume,	choroidal	thinning,	and	wider	retinal	venules;	but	has	
normal	RNFL,	macular	volume,	retinal	arterioles,	retinal	vessel	tortuosity,	and	
retinal	vessel	fractal	dimension.	
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 Corticobasal	degeneration	is	associated	with	partial	macular	thinning,	reduced	
macular	volume,	reduced	GCL	volume,	choroidal	thinning,	wider	retinal	
venules,	and	reduced	retinal	arteriolar	fractal	dimension;	but	has	normal	RNFL,	
retinal	arterioles,	retinal	vessel	tortuosity,	and	retinal	venular	fractal	
dimension.	
	
 Posterior	cortical	atrophy	is	associated	with	nasal	RNFL	thinning,	choroidal	
thinning,	and	reduced	retinal	arteriolar	and	venular	fractal	dimension;	but	has	
normal	retinal	arterioles,	and	retinal	vessel	tortuosity.	(Macular	parameters	of	
volume	were	not	assessed.)	
	
 None	of	these	neuroretinal	markers	independently	discriminated	between	all	
the	dementia	types	with	high	specificity.	Although	arterio‐venous	ratio	
discriminated	between	AD	and	PPA,	and	arteriolar	fractal	dimension	between	
CBD	and	PPA,	and	between	PCA	and	PPA.	However,	in	combination,	the	pattern	
of	neuroretinal	involvement	across	all	the	markers	does	discriminate	between	
all	the	dementia	types.		
	
 Correlation	with	ACE‐III	scores	was	also	poor,	except	for	a	positive	correlation	
with	macular	volume	in	PPA.		
	
ALS	
 Amyotrophic	lateral	sclerosis	is	associated	with	a	thinner	RNFL	in	a	small	
cluster	of	patients,	thinner	choroid	when	on	riluzole	treatment,	and	a	reduced	
arteriolar	and	venular	fractal	dimension;	but	has	normal	RNFL	(in	most	
patients),	macular	thickness,	macular	volume,	macular	GCL	volume,	retinal	
vessel	calibre	and	retinal	vessel	tortuosity.	
	
 Bulbar‐onset	amyotrophic	lateral	sclerosis	is	associated	with	a	thinner	PMB	
sector	of	RNFL,	and	reduced	arteriolar	fractal	dimension;	but	has	normal	
macular	thickness,	macular	volume,	macular	GCL	volume,	retinal	vessel	calibre	
and	retinal	vessel	tortuosity	
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 Spinal‐onset	amyotrophic	lateral	sclerosis	is	not	associated	with	any	
neuroretinal	marker,	with	no	value	significantly	different	from	controls.	
	
 Regarding	discrimination	between	ALS	subtypes,	arteriolar	tortuosity	and	
arteriolar	fractal	dimension	both	discriminated	between	bulbar‐onset	and	
spinal‐onset	ALS.	
	
Methodological	advancements	
A	substantial	component	of	this	thesis	has	been	the	detailed	description	of	the	methods	
of	retinal	imaging	in	relation	to	acquisition,	processing	and	interpretation	of	the	
imaging,	and	how	this	underpins	any	research	data	output.	This	depth	of	study	and	
scrutiny	of	the	imaging	procedure	requires	a	solid	understanding	of	retinal	structure	
and	function,	as	well	as	experience	in	the	use	of	the	retinal	imaging	devices.	
In	addition,	the	protocols	established	for	this	study,	whilst	sufficiently	interoperable	
with	comparable	studies	in	the	literature,	contain	a	higher	level	of	quality	assurance	
and	detailed	procedure	of	image	processing	that	is	often	missing	from	published	work.	
In	fact,	the	figures	within	some	published	papers	occasionally	‘red‐flag’	the	study	as	
without	sufficient	scientific	rigor	when	basic	image	processing	techniques	are	clearly	
absent.	For	example,	ignoring	the	foveal	location	of	RNFL	scans.	This	appears	a	minor	
step	to	the	inexperienced	observer,	but	failure	to	account	for	this	can	generate	garbage	
RNFL	data	that	can	lead	to	wrong	conclusions.	
The	modulation	of	vessel	analysis	software	to	provide	semi‐automatic	quantitative	
vessel	metrics	from	the	SPECTRALIS	SLO	images	is	a	novel	development,	and	one	that	
should	not	be	undervalued.	The	process	and	evaluation	of	this	has	already	been	
published	in	a	leading	medical	imaging	journal.97	In	an	industry	that	is	led	by	large	and	
well‐resourced	technical	companies,	with	proprietary	IT	development	teams	and	
products,	software	developments	such	as	this	are	rare	from	small	research	groups.			
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Pathology	and	mechanisms	
GCL	versus	RNFL	
There	are	weaknesses	in	the	broad	interpretation	of	RNFL	thickness.		
The	RNFL	consists	of	more	than	just	axons.	And	RNFL	thinning	does	not	distinguish	
between	axonal	thinning,	axonal	loss,	or	other	tissue	atrophy	within	the	layer.	In	
addition,	pRNFL	scan	is	a	single	circular	scan	around	the	disc,	giving	thickness	across	a	
single	position	in	the	anterior	pathway.		
Measurement	of	GCL	thickness	‐	or	volume	‐	is	potentially	a	superior	marker	of	RGC	
integrity.	It	can	be	used	to	measure	damage	soon	after	an	ON	episode,	unlike	the	RNFL	
where	there	may	still	be	inflammation/swelling	precluding	its	use	for	measuring	
axonal	loss	in	the	first	few	months	after	ON.311	
In	the	study	of	MS	biomarkers	in	this	research,	I	have	compared	RNFL	and	GCL	in	many	
parts	of	the	analysis,	and	concluded	that	the	choice	of	measure	depends	upon	the	
circumstances	and	clinical	question,	but	that	in	general	GCL	measures	are	more	
sensitive	and	reliable	than	RNFL.	
	
On	the	subject	of	RGC	loss	pathophysiology,	I	remain	unconvinced	that	the	observed	
RNFL	and	GCL	thinning	in	neurodegeneration	is	simply	the	product	of	retrograde	trans‐
synaptic	degeneration,	spreading	towards	the	eye	when	the	visual	pathways	become	
involved	in	the	intracranial	pathology.	The	evidence	from	MS	(selective	temporal	loss)	
and	Alzheimer’s	disease	(no	loss	of	neurones	in	LGN209)	in	conjunction	with	many	
observed	findings	in	this	research	project	suggests	that	RGCs	are	selectively	and	
directly	targeted	in	different	diseases,	and	in	different	ways.	In	MS,	to	the	RGC	cell	body	
first.	In	dementia,	perhaps	a	toxic	effect	of	amyloid‐β	in	the	RGC.312	
In	ALS,	several	mechanisms	have	been	proposed	to	explain	the	relentless	and	
progressive	character	of	the	disease,	and	how	it	‘spreads’	through	the	motor	system.	
Degenerative	patterns	of	‘dying‐forward’	and	‘dying‐back’	of	the	motor	neurone	have	
been	demonstrated,	and	therefore	both	anterograde	and	retrograde	degeneration	
processes	of	the	neurone.	With	RGC	involvement	in	only	some	cases	of	ALS,	this	pushes	
the	hypothesis	again	to	some	specific	pathologies	targeting	the	RGC,	with	others	
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avoiding	it,	until	perhaps	very	late	stage	disease,	where	retrograde	trans‐synaptic	
degeneration	towards	the	eye	may	occur.	
Genetics	may	ultimately	answer	this	question	in	ALS.	New	genes	in	the	pathogenesis	of	
ALS	are	being	discovered	all	the	time.	Three	genes	so	far	linked	with	ALS	are	also	
linked	with	glaucoma	and	optic	neuropathy	(ataxin‐2,	optineurin,	tank‐binding	kinase	
1).313‐315	Therefore	it	is	possible	that	the	observed	impact	on	the	RGC	in	some	patients	
is	a	consequence	of	the	root	pathological	cause.	
In	MS,	the	RGC	is	selectively	targeted,	as	with	the	brain	white	matter	tracts,	and	in	
terms	of	inflammation,	and	in	demyelination.	Therefore,	are	the	oligodendrocytes	of	
the	anterior	visual	pathways	similar	to	the	brain	oligodendrocytes?	Are	they	
functionally	and	structurally	similar?	Inflammation	in	the	anterior	visual	pathway	is	
perhaps	IL‐17	driven316,	unlike	in	the	spinal	cord.	
I’ve	looked	in	this	research	at	RGC	(GCL	and	RNFL)	but	there	is	some	emerging	
suggestion	for	deeper	retinal	layers	to	be	involved	in	MS,	such	as	the	inner	plexiform	
layer.317	Although	these	changes	may	be	dynamic,	rather	than	simply	atrophic.318	
Therefore,	the	hypothesis	relating	the	eye	to	the	brain,	as	simply	an	end	extrusion,	with	
retrograde	degeneration	perhaps	needs	modification.	The	eye	is	as	much	part	of	the	
brain	as	any	other	location,	and	as	all	brain	disease	preferentially	affect	specific	parts	of	
the	brain	‐	at	least	in	their	early	stage	‐	then	the	eye	is	included	within	this.	
This	makes	the	eye	more	powerful	as	a	window	to	the	brain,	as	the	presence	and	
pattern	of	involvement	if	the	eye	in	brain	disease	is	specific,	rather	than	surrogate	end	
marker	of	global	brain	atrophy.	Ans	therefore	it	is	essential	to	know	which	diseases	
involve	the	eye,	how	they	involve	the	eye,	and	how	we	can	use	that	information	to	
benefit	patient	care.	
This	study	has	developed	this	idea	of	specific	patterns	that	we	can	observe	in	the	eye,	
and	attempted	to	quantify	the	degree	of	specificity	and	sensitivity	of	correlation	with	
phenotype,	with	existing	markers	of	disease	and	prognostic	utility.	Our	evolving	
understanding	of	disease	pathophysiology	complements	this	research,	and	it	is	likely	
that	we	will	see	further	evidence	for	the	specific	involvement	of	the	eye	in	these	
diseases,	confirming	the	findings	from	this	and	other	studies	on	the	subject.	
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Limitations	and	Cautions	
Study	limitations	
The	primary	limitation	of	this	study	is	that	it	is	cross‐sectional.	This	is	satisfactory	for	
diagnostic	phenotyping	and	discrimination,	but	leaves	some	unanswered	questions	
regarding	the	natural	history	of	neuroretinal	metrics,	in	relation	to	disease	trajectory.	
A	longitudinal	study	would	add	value	to	determine	the	temporal	relationship	of	
neuroretinal	changes,	and	particularly	timing	of	any	changes	in	relation	to	
development	of	the	syndromic	symptoms,	so	do	the	changes	happen	before,	early	or	
during	the	disease.	It	would	also	enable	prospective	recording	of	ON	episodes,	which	
would	better	aid	understanding	of	the	impact	of	optic	neuritis	on	the	GCL.		
I	have	also	used	only	right	eye	data,	to	avoid	confounding	bias	issues	from	units	of	
analysis	paired	clustering.	However,	I	have	gone	through	the	data	and	carried	out	
identical	comparisons	of	left	eye	data	for	the	majority	of	the	analyses	presented	here,	
and	they	matched	without	exception.	
Ocular	Disease	
The	growing	number	of	studies	providing	evidence	of	abnormal	retinal	structural	
measurements	in	diseases	viewed	as	predominantly	non‐ocular	also	has	important	
implications	for	the	management	of	ophthalmic	disease.	For	example,	RNFL	thinning	
due	to	neurological	diseases	may	complicate	the	management	of	glaucoma	in	which	
measurement	of	change	in	RNFL	thickness	over	time	is	commonly	used	to	detect	
progression.	Particularly	in	the	elderly	population	where	comorbidity	is	common,	a	
condition	such	as	dementia,	which	appears	to	be	associated	with	RNFL	thinning,	may	
introduce	a	potentially	confounding	factor	to	the	assessment	of	glaucoma	
progression.319		
On	the	other	hand,	the	observation	that	diseases	such	as	glaucoma	and	dementia	have	
shared	features	raises	the	possibility	that	neuroprotective	treatments	effective	for	one	
disease	may	be	utilised	for	another.	For	example,	neuroprotective	and	
neuroregenerative	treatments	that	aim	to	protect	existing	and	regenerate	damaged	
cells	respectively	may	be	effective	for	a	range	of	diseases	with	heterogeneous	
mechanisms	from	Alzheimer’s	disease	to	glaucoma.320,	321	
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The	ability	to	identify	ocular	biomarkers	of	systemic	disease	is	an	attractive	prospect	as	
the	optical	properties	of	the	eye	permit	visualisation	of	vascular	and	neural	tissues	that	
is	not	possible	in	any	other	part	of	the	body.	The	identification	of	ocular	biomarkers	of	
systemic	and	predominantly	non‐ocular	disease	is	not	a	new	concept	and	it	is	clear	that	
many	ocular	diseases,	such	as	diabetic	retinopathy	and	arteritic	ischemic	optic	
neuropathy	are	a	direct	consequence	of	systemic	pathology.	In	fact,	the	diabetic	
retinopathy	grading	system	is	an	excellent	example	of	the	use	of	ocular	biomarkers	for	
monitoring	a	systemic	disease,	with	other	useful	diabetes	biomarkers	including	HbA1c	
and	blood	pressure.	The	introduction	of	OCT	has	though,	led	to	the	realisation	that	an	
increasing	number	of	conditions	can	have	ocular	manifestations,	and	it	is	possible	to	
quantify	these	changes	using	imaging	devices.		This	raises	the	possibility	that	OCT	
imaging	might	reduce	the	need	for	more	invasive,	time	consuming	or	costly	tests,	for	
example	reducing	the	need	for	MRI	imaging	of	the	brain	to	monitor	for	disease	
progression	in	multiple	sclerosis.	Measurements	from	OCT	may	be	used	for	diagnoses,	
assessing	disease	progression,	for	predicting	clinical	outcomes,	or	for	providing	more	
acceptable	and	cost‐effective	ways	to	assess	the	effect	of	new	treatments.	In	clinical	
trials,	appropriately	used	biomarkers	have	the	potential	to	replace	or	supplement	
conventional	endpoints	with	something	that	can	be	measured	earlier,	more	easily	and	
more	frequently.322	
Utility	as	biomarkers	
We	should	though	exercise	caution	when	considering	introducing	new	biological	
markers,	particularly	if	considering	them	for	inclusion	as	endpoints	in	clinical	trials	or	
to	base	decision‐making	regarding	effectiveness	of	treatment.	Few	biomarkers	fully	
capture	the	full	effect	of	treatment,	and	this	is	particularly	likely	to	be	true	for	ocular	
biomarkers	of	systemic	diseases.323	Nevertheless,	there	is	great	hope	that	
quantification	of	retinal	parameters	using	OCT	may	be	a	useful	surrogate	for	the	
assessment	of	a	wide	range	of	predominantly	non‐ocular	diseases.	
The	ultimate	goal	with	neurodegenerative	disease	is	of	course	prevention.	This	will	
require	a	combination	of	strategies,	from	early	identification	of	individuals	at	risk,	to	
modification	of	that	risk.	Until	that	becomes	possible,	then	our	strategy	is	to	slow	down	
the	disease	process,	halt	it,	and	eventually	reverse	the	degenerative	damage	done.	All	
these	interventions	will	require	reliable	and	well‐researched	biomarkers	of	the	disease,	
both	in	diagnostic	discrimination	and	also	in	disease	monitoring.		
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There	is	increasing	evidence	that	no	single	biomarker	will	in	itself	be	sufficient	to	
characterise	an	individual	in	term	of	their	disease	and	likely	trajectory.	Stratified	
medicine	identifies	that	the	future	of	managing	these	difficult	conditions	is	
personalised	diagnosing	and	treating,	with	multi‐modal	and	combination	investigations	
and	tests,	from	genetic	profiling	to	detailed	clinical	assessment,	to	imaging	biomarkers.	
In	cancer	treatment,	for	example,	a	personal	workup	of	all	these	factors	is	pivotal	in	
titrating	the	most	appropriate	treatment	regime	for	the	individual	patients,	as	well	as	
understanding	their	likely	disease	course.	This	is	a	great	advance	from	when	cancer	
diagnoses	were	only	dichotomised	based	on	the	presence	of	metastases,	and	treated	
accordingly.	
Across	the	diseases	of	multiple	sclerosis,	dementia	and	motor	neurone	disease,	there	is	
varying	understanding	of	the	disease	pathophysiology,	and	where	to	target	possible	
treatments,	with	MS	perhaps	the	furthest	ahead	in	disease	modifying	therapeutics.	
However,	there	is	some	commonality	in	how	we	might	use	biomarkers	to	diagnose	and	
monitor	these	dissimilar	diseases,	with	imaging	markers	such	as	retinal	imaging	a	
plausible	candidate.	
Ultimately,	with	no	‘gold	standards’	of	diagnosis	or	monitoring	in	dementia,	it	is	hard	to	
fully	explore	and	determine	the	utility	of	neuroretinal	biomarkers.	Better	disease	
genotyping	may	provide	a	useful	comparator	in	the	future,	and	allow	us	to	realise	the	
potential	of	the	retina	in	informing	on	these	complex	diseases.	In	the	meantime,	we	can	
continue	to	explore	the	utility	of	the	retina	in	providing	prognostic	disease	markers,	in	
longitudinal	studies	of	disease	manifestations	such	as	cognitive	and	psychological	
changes.	
The	emergence	of	retinal	imaging	derived	markers	of	neurodegenerative	disease	is	a	
very	young	field,	with	a	surge	of	interest	over	the	last	few	years	‐	mainly	a	result	of	new	
ocular	imaging	technologies	such	as	OCT	providing	the	ability	to	provide	incredible	
images,	with	resolutions	suitable	for	precise	measures	of	neuronal	integrity.	
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Retinal	imaging	in	neuroscience	research	
	
Optical	coherence	tomography	
Retinal	imaging	is	very	much	an	ophthalmic	sub‐specialty	in	its	own	right,	with	most	
ophthalmology	departments	employing	dedicated	ophthalmic	photographers	with	
particular	expertise	in	all	aspects	of	ocular	imaging,	from	external	macro‐photography	
to	micron‐level	retinal	analysis.	
The	emergence	of	OCT	has	transformed	ophthalmic	investigation	and	management,	and	
created	an	exciting	area	within	the	world	of	retinal	imaging.	The	rapid	evolution	of	the	
technology,	in	conjunction	with	the	inherent	ease‐of‐use	and	patient‐acceptability	of	
the	test,	have	made	it	not	only	an	essential	tool	in	clinical	ophthalmology,	but	now	an	
exciting	research	tool	in	new	areas	such	as	neurology.			
The	images	created	by	the	latest	OCT	machines	are	stunning.	The	micron‐level	
resolution	along	with	software	refinements	of	image	averaging	and	noise	reduction	
facilitate	clear	and	logical	images,	that	easily	visually	represent	the	retina	in	health	and	
in	disease.		The	ability	to	also	generate	quantitative	measures	of	retinal	layer	
thicknesses	and	volumes	automatically	is	a	powerful	capability,	and	one	that	enables	
drastically	improved	patient	care	in	the	management	of	diseases	such	as	age‐related	
macular	degeneration	(ARMD)	and	also	aids	the	research	use	of	OCT	in	defining	and	
learning	the	sub‐clinical	retinal	changes	occurring	in	both	ocular	and	systemic	diseases.			
The	value	of	measuring	neuroretinal	alterations	in	brain	diseases	is	a	rapidly	growing	
area	of	research,	with	exponential	growth	in	published	work	and	conference	interest.	
The	benefits	of	OCT	as	a	clinical	investigation	are	quite	clear.	The	extent	of	superiority	
over	traditional	brain	imaging	technologies	are	becoming	better	understood,	as	are	the	
aspects	where	OCT	provides	complementary	information	that	is	useful	clinically.	
It	is	of	course	essential	to	also	have	an	experienced	ophthalmologist	to	interpret	the	
OCT	images.	Someone	who	understands	the	pathophysiology	and	natural	history	of	
retinal	disease,	the	differential	diagnosis	of	abnormalities	or	incidental	findings,	as	well	
the	correct	decisions	in	relation	to	disease	monitoring	or	treatment	plans.	As	with	any	
new	imaging	technology,	the	accessible	visual	image	can	result	in	the	technology	being	
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mistaken	for	simplicity,	where	in	fact	subtleties	of	image	acquisition,	processing,	and	
interpretation,	can	be	missed	and	erroneous	conclusions	made.		
A	final	important	consideration	is	whether	patients	included	in	OCT‐device	normative	
databases	might	have	systemic	diseases	that	affect	the	RNFL	layer	and	thereby	affect	
the	ability	of	these	databases	to	detect	ophthalmic	disease.	Normative	databases	are	
often	used	to	categorise	patients	with	suspected	glaucoma	as	within	normal	limits,	
borderline,	or	outside	normal	limits,	and	although	the	databases	differ	in	size,	eligibility	
criteria	and	ethnic	makeup	between	manufacturers324,	all	exclude	patients	with	
diseases	known	to	affect	the	retina	or	optic	nerve.	It	is	however,	apparent	that	a	
growing	number	of	conditions	may	result	in	retinal	changes,	not	previously	
appreciated,	meaning	the	exclusion	criteria	may	need	to	be	refined.	
	
Future	developments	in	retinal	imaging	
Adaptive	optics	OCT	
Adaptive	optics	(AO)	is	an	optical	system	of	real‐time	correction	of	motion	or	
aberration.	The	system	has	previously	been	integrated	into	fundus	cameras	and	
scanning	laser	ophthalmoscopes,	where	it	can	improve	image	quality,	although	with	the	
drawbacks	of	limited	field	of	view	and	depth	of	focus.325	
Its	natural	home	is	with	integration	into	OCT	systems,	where	it	can	not	only	reduce	blur	
and	image	artefact,	but	also	increase	the	resolution	of	the	image,	particularly	in	the	
lateral	direction,	where	standard	OCT	is	limited	to	around	20µm	resolution,	AO	
improves	this	to	3‐4µm	‐	identical	to	the	axial	resolution	‐	enhancing	the	full	3D	detail	
and	precision.	
One	area	of	current	interest	is	the	(automated)	measurement	of	3D	lamina	cribrosa	
microstructure	using	AO‐OCT.	Posterior	deformation	of	the	lamina	cribrosa	is	thought	
to	be	the	cause	and	site	of	axonal	injury	in	some	patients	with	glaucoma,	and	therefore	
understanding	this	structure	and	the	pores	within	it	that	support	the	RGC	axons,	could	
be	an	important	tool	in	glaucoma	diagnosis.326	
Polarisation	Sensitive	OCT	
Polarisation	sensitive	OCT	(PS‐OCT)	is	a	hardware	adaptation	of	a	conventional	OCT	
system,	generating	additional	contrast	in	images,	based	upon	the	polarisation	
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properties	of	the	tissue	being	examined.	Its	utility	in	the	assessment	of	neuroretinal	
integrity	is	unclear,	but	it	may	offer	a	method	of	detecting	axonal	compromise	earlier	
than	existing	OCT	imaging,	extrapolating	from	results	of	its	performance	in	evaluating	
outer	retinal	pathology.327	
	
OCT‐angiography	
OCT	angiography	(OCT‐A)	is	an	innovative	evolution	of	OCT	technology,	generating	
remarkable	depth‐resolved	images	of	the	retinal	micro‐circulation,	without	the	need	
for	intravenous	contrast.	The	microvascular	vessel	information	is	extracted	from	the	
standard	OCT	image	data,	with	specialised	‐	and	intensive	‐	processing	to	identify	the	
vessels.	The	resulting	angiographic	image	is	remarkable,	and	enchanting	many	retinal	
researchers.	(Fig.	7.1)	Several	variants	of	the	technology	are	available,	using	one	or	
both	of	Doppler	shift	(phase	variance),	and	decorrelation	(speckle	variance)	processes.		
	
	
Figure	7.1:	AngioMontage	‐	overlaid	single	3x3mm	OCT‐A	images	from	the	Heidelberg	OCT‐A	
device,	to	create	a	full	optic	nerve	head	and	macular	angiographic	image	
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The	standard	OCT‐A	image	provides	no	absolute	flow	or	velocity	information,	only	the	
presence	of	flow	above	a	threshold	low	level.	However,	much	work	is	being	done	to	
develop	quantitative	measures	of	flow	from	these	images.	Glaucoma	is	an	area	of	
particular	relevance	and	interest	for	determining	microvascular	flow,	in	and	around	the	
optic	nerve	head,	and	work	on	this	is	progressing	well.328,	329	(Fig.	7.2)	
	
	
Figure	7.2:	Comparisons	of	4.5mm	OCT‐A	images	and	color‐coded	perfused	capillary	density	
maps	in	a	normal,	a	severe	POAG,	and	a	severe	NTG	patient.	First	column:	grayscale	OCT‐A	
images	generated	using	SSADA	algorithm.	Second	column:	thresholded	binary	images	
containing	only	the	perfused	capillaries	after	the	removal	of	major	blood	vessels.	Third	column:	
corresponding	colour‐coded	perfused	capillary	density	maps.	Last	column:	superimposed	image	
of	the	colour	maps	and	the	inverted	OCT‐A	images.  
[Image	from	Scripsema	et	al.	IOVS	2016	329]		
	
Absolute	measures	of	flow	within	the	microvasculature	remains	a	goal	for	OCT‐A	
systems.	Variable	interscan	time	analysis	(VISTA)	is	a	step	towards	this,	providing	
relative	flow	information.	This	is	achieved	by	multiple	imaging	of	the	same	location,	but	
varying	the	cut‐off	threshold	level	for	determining	whether	a	vessel	segment	will	
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appear	in	the	image	(flow)	or	not	appear	(no	or	slow	flow).	By	varying	this	threshold,	
and	then	applying	a	colour	scale	to	the	vessels	per	their	presence	at	varied	thresholds,	
a	relative	flow	map	is	produced.	(Fig.	7.3)	
	
	
Figure	7.3:	Variable	interscan	time	analysis	(VISTA)	modification	of	OCT‐A,	to					
provide	relative	flow	information	on	a	colour	scale;	blue	(slow)	to	red	(fast)	
	
The	key	strength	of	OCT‐A	imaging	is	the	ability	to	visualise	flow	in	the	retinal	
microcirculation,	without	the	need	for	an	intravenous	injection	of	fluorescent	dye.	
The	limitation	at	present	is	that	OCT‐A	is	based	on	the	motion	of	blood	flow,	but	does	
not	at	this	stage	inform	on	the	dynamic	of	that	flow,	nor	any	information	regarding	the	
vessel	wall,	its	permeability,	inflammatory	changes	or	other	manifestations	of	extra‐
luminal	blood	leakage.	
OCT‐A	is	therefore	likely	to	be	part	of	combination	imaging	over	the	next	decade,	rather	
than	a	single	overarching	imaging	system.	
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OCT‐Leakage	
OCT‐Leakage	is	a	software	innovation	in	OCT	technology,	that	has	recently	been	
proposed	as	a	potential	new	non‐invasive	method	for	identifying	and	mapping	
abnormal	retinal	oedema	that	is	leaking	from	nearby	vessels.330	The	chief	limitation	
and	complaint	regarding	OCT	and	OCT‐A	technologies	has	been	the	inability	to	identify	
leakage,	in	a	way	comparable	with	the	fluorescein	angiogram.	However,	this	new	
development	claims	to	have	achieved	this,	and	with	even	better	sensitivity	than	
fluorescein	angiography.331	It	is	too	early	to	know	if	this	technology	matches	up	to	the	
headlines,	however	it	is	the	first	to	target	this	unmet	need.	
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Future	work	
	
Widening	the	field	
The	SLO	images	I	used	in	this	research	study	‐	extracted	from	the	SPECTRALIS	OCT	
device	‐	had	a	field	of	view	of	35°.	This	is	sufficient	to	view,	and	analyse,	the	first	and	
second‐order	vessels,	but	we	are	only	seeing	a	small	part	of	the	retinal	vasculature.	
This	was	sufficient	to	report	wider	venules	in	MS,	perhaps	associated	with	
inflammation.	However,	we	know	clinically	that	visibly	inflamed	vessels	are	typically	in	
the	mid‐to‐far	periphery,	and	therefore	wide‐angle	vessel	analysis	may	be	more	
sensitive	to	changes,	and	more	clinically	useful.	
Optos	is	a	world	leader	in	wide‐field	retinal	imaging	devices,	such	as	the	P200	Daytona.	
(Fig.	7.4)	the	wide‐field	retinal	images	are	terrific	(Fig.	7.5),	and	work	has	already	been	
done	on	vessel	morphological	assessment	in	there	SLO	images.280	Such	a	device	is	now	
located	in	the	ARRNC	where	I	performed	my	research	study,	and	so	could	be	used	in	
future	work	to	look	at	the	peripheral	blood	vessels	in	patients	with	MS,	and	other	
neurodegenerative	diseases.	
	
 
Figure	7.4:	Optos	Daytona	P200	wide‐field	SLO	device						
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Figure	7.5:	Sample	images	from	Optos	Daytona	P200	wide‐field	SLO	device						
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Big	data	
One	of	the	biggest	challenges	during	my	research	was	manually	collecting,	and	
processing	all	the	clinical	and	imaging	data.	With	no	master	database	or	routine	
collection	system,	every	phenotypic	detail	had	to	be	retrieved	individually.	The	benefits	
of	an	electronic	system	providing	the	infrastructure	for	a	routine	data	collection	culture	
within	a	research	facility	are	immense.	Providing	not	only	routine	clinical	audit	data	for	
quality	improvement	activities	in	patient	care,	but	a	substantial	resource	for	any	
clinical	research	projects	that	rely	upon	accurate	and	comprehensive	phenotypic	data.	
Modern	data	policies	allow	for	anonymised	data	to	be	used	in	this	way,	provided	
consent	is	given	at	the	point	of	entry.	
In	a	world	where	‘big	data”	is	becoming	more	of	a	cliché	than	actual	use,	it	is	time	to	
embrace	the	benefits	of	systems	that	can	collect	and	organise	data	in	this	way,	and	to	
operators	who	are	trained	in	the	handling	and	reporting	of	this	complex	data	resource.	
And	indeed,	for	medical	challenges	such	as	neurodegenerative	disease,	where	it	is	clear	
that	complex	multifactorial	risks	and	genetics	are	at	play,	then	it	is	only	through	large	
patient	populations,	deeply	phenotyped	and	genotyped,	that	signals	will	emerge	that	
point	us	towards	clues,	and	ultimately	treatment	targets.	
Imaging	workload		
In	this	research	project,	I	recruited	and	imaged	961	participants	(655	MS,	140	
dementia,	20	ALS,	and	166	total	controls).	Each	imaging	set	required	quality	assurance,	
and	image	processing/correction	as	outlined	in	Chapter	3.	In	addition,	the	secondary	
processing	of	the	SLO	images	with	VAMPIRE	software	took	around	many	hundreds	of	
hours	of	work.	
Whilst	the	tools	I	used	were	user‐friendly,	and	I	have	extensive	experience	in	using	
them,	this	makes	the	work	different	from	those	who	use	the	imaging	data	from	MRI	etc	
where	the	process	of	capturing	and	transferring	the	images	is	performed	by	other	staff.	
There	are	benefits	of	being	personally	responsible	for	capturing	the	images:	identifying	
patterns	or	trends	in	the	images,	that	may	result	in	testable	hypotheses	or	new	
findings;	real‐time	processing;	and	immediate	clinical	feedback	to	the	
patients/participants,	which	enhances	their	satisfaction	with	participating	in	research,	
as	well	as	providing	a	clinic	role,	and	being	able	to	address	any	incidental	findings	as	
they	occur.	
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Final	thoughts	
	
It	is	not	certain	which	poet	or	philosopher	first	proclaimed	the	eye	as	a	‘window	to	the	
soul’,	but	many	since	have	been	fascinated	and	seduced	by	the	extraordinary	nature	of	
our	eyes	and	our	visual	sense.	Over	the	centuries,	metaphysical	ideas	on	the	nature	of	
our	ocular	system	have	converged	with	scientific	understanding	of	visual	pathway	
anatomy	and	ocular	physiology,	to	a	point	where	we	now	have	a	detailed	insight	into	
how	our	eyes	work,	whilst	maintaining	a	healthy	respect	for	the	preciousness	of	our	
sight,	albeit	with	a	less	supernatural	stance.	
The	eye	as	a	‘window	to	the	body’	is	a	compelling	concept.	Studying	the	eye	has	
benefited	greatly	from	advances	in	technology,	clinical	medicine,	and	biomedical	
research,	enabling	new	discoveries	on	the	eye’s	role	in	systemic	diseases	such	as	
hypertension	and	diabetes.	Imaging	of	the	eye	fulfils	many	of	the	criteria	to	be	an	
acceptable	patient	investigation	and	even	a	screening	tool.	This	relies	upon	us	
identifying	reliable	biomarkers	of	pre‐symptomatic	disease	at	the	same	time	as	we	
uncover	effective	treatments	or	interventions.	
The	eye	as	an	‘extension	of	the	brain’	provides	us	with	an	intriguing	opportunity	to	
complement	the	variety	of	tools	we	use	in	neuroscience	to	research	the	function	and	
dysfunction	of	our	brain,	with	the	ability	to	directly	visualise	this	forward	projection	of	
brain	tissue,	and	examine	its	structure	and	function	in	extreme	detail.		
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